

REMARKS

Claims 37-41 and 44-106 are in the application. The claims were previously amended in Applicants response of 3 August 2010.

The Examiner has presented a revised restriction requirement under 35 USC §121 to the following two groups:

Group I, claims 37-41 and 44-72 drawn to multi-component dosage forms;

Group II, claims 73-106 drawn to a capsule dosage form.


Applicants elect group II, with traverse. The subject matter of Group II drawn to “a capsule dosage form” presents the same burden on the examiner for searching as review of the claims of Group I. The only difference between these two groups is that in group I the solid matrix is comprised of the extruded and injection molded composition, and the capsule shell is undefined, whereas in Group II it is the capsule shell being comprised of the extruded and injection molded composition, and the solid matrix is undefined. The composition of the material is the same in both.

Applicants affirm their election of species as previously presented. Applicants respectfully request reconsideration and withdrawal of the restriction to the claims.

A copy of the most recent office action and/or Notice of Allowance in Applicants copending applications 10/060849 and 10/470438 are enclosed herewith.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



/ /
Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017 Facsimile (610) 270-5090